Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01010399
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:20.725096+00:00
Published At
2012-04-18T00:00:00+00:00
Record Updated At
2012-04-18
Results Posted At
2012-04-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hypertriglyceridemia", "HIV Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2012-04-18"
protocolSection.identificationModule.nctId
"NCT01010399"
protocolSection.identificationModule.officialTitle
"A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza\u00ae in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva\u00ae 1400mg Plus Norvir\u00ae 100mg Plus Optimized Background"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2012-04-18"

Study condition terms

  • Hypertriglyceridemia (protocolSection.conditionsModule.conditions)
  • HIV Infection (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.